Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 16/20 | 0.79 |
| ▸ | DRD4 | P21917 | 2/20 | 0.49 |
| ▸ | CCR2 | P41597 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1675042 | 0.94 | F10 (0.87) | F10DRD4CCR2F2 | |
| SCHEMBL8358548 | 0.92 | F10 (0.66) | F10F2PPARG | |
| SCHEMBL15911461 | 0.89 | F10 (0.63) | F10DRD4CCR2 | |
| SCHEMBL1675257 | 0.89 | F10 (1.00) | F10DRD4F2 | |
| SCHEMBL1675035 | 0.88 | F10 (0.82) | F10DRD4CCR2F2 | |
| SCHEMBL1675474 | 0.88 | F10 (0.82) | F10CCR2F2 | |
| SCHEMBL1675142 | 0.87 | F10 (0.87) | F10DRD4F2 | |
| SCHEMBL1675121 | 0.85 | F10 (0.78) | F10DRD4CCR2F2 | |
| SCHEMBL15911644 | 0.82 | F10 (0.68) | F10DRD4CCR2 | |
| SCHEMBL8358647 | 0.82 | F10 (0.86) | F10F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4664592-B2 | — | — | 2011-04-06 | — | — | JP | claimed |
| US-20090069565-A1 | NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-03-12 | — | — | US | disclosed |
| US-20090069565-A1 | NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069565-A1 | NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS | F12, F5, F2 | F10 10/4885DRD4 1029/4885CCR2 1071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.